Anti- PD-1/PD-L1 has yielded significant benefits for patients with NSCLC by inhibiting immune checkpoint activity, and the study demonstrated that HLA-DRB1 enhances the efficacy of anti-PD-1 therapy90. Here, HLA-DRB1 is linked to non-small cell lung carcinoma.